0.25
price down icon3.85%   -0.01
after-market 시간 외 거래: .25
loading
전일 마감가:
$0.26
열려 있는:
$0.275
하루 거래량:
201.75K
Relative Volume:
1.00
시가총액:
$9.76M
수익:
-
순이익/손실:
$-117.67M
주가수익비율:
-0.0809
EPS:
-3.09
순현금흐름:
$-101.06M
1주 성능:
-18.03%
1개월 성능:
-33.16%
6개월 성능:
-41.18%
1년 성능:
-90.00%
1일 변동 폭
Value
$0.25
$0.2849
1주일 범위
Value
$0.25
$0.3281
52주 변동 폭
Value
$0.25
$3.67

Athira Pharma Inc Stock (ATHA) Company Profile

Name
명칭
Athira Pharma Inc
Name
전화
(425) 620-8501
Name
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
직원
26
Name
트위터
Name
다음 수익 날짜
2024-12-07
Name
최신 SEC 제출 서류
Name
ATHA's Discussions on Twitter

ATHA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ATHA
Athira Pharma Inc
0.25 9.76M 0 -117.67M -101.06M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-09-19 다운그레이드 Mizuho Outperform → Neutral
2024-09-04 다운그레이드 BTIG Research Buy → Neutral
2024-09-04 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2024-09-04 다운그레이드 Rodman & Renshaw Buy → Neutral
2024-08-19 개시 Rodman & Renshaw Buy
2022-10-17 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2022-07-07 개시 Mizuho Buy
2022-06-23 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2022-06-23 다운그레이드 Jefferies Buy → Hold
2022-06-23 다운그레이드 Stifel Buy → Hold
2022-05-10 개시 BTIG Research Buy
2022-04-21 개시 Berenberg Buy
2021-12-15 개시 Goldman Neutral
2020-10-13 개시 Goldman Buy
2020-10-13 개시 JMP Securities Mkt Outperform
2020-10-13 개시 Jefferies Buy
2020-10-13 개시 Stifel Buy
모두보기

Athira Pharma Inc 주식(ATHA)의 최신 뉴스

pulisher
Mar 27, 2025

Athira Pharma stock hits 52-week low at $0.3 amid steep decline By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Athira Pharma stock hits 52-week low at $0.3 amid steep decline - Investing.com Australia

Mar 27, 2025
pulisher
Mar 13, 2025

What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News

Mar 13, 2025
pulisher
Mar 11, 2025

Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Athira Pharma stock hits 52-week low at $0.33 amid steep decline By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 07, 2025

Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga

Mar 07, 2025
pulisher
Mar 03, 2025

Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks

Mar 03, 2025
pulisher
Mar 02, 2025

Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN

Mar 02, 2025
pulisher
Feb 27, 2025

Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Athira Pharma, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire

Feb 27, 2025
pulisher
Feb 26, 2025

Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia

Feb 26, 2025
pulisher
Feb 25, 2025

Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 24, 2025

Athira Pharma Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView

Feb 24, 2025
pulisher
Feb 21, 2025

ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Molecular Partners (NASDAQ:MOLN) versus Athira Pharma (NASDAQ:ATHA) Head to Head Review - Defense World

Feb 21, 2025
pulisher
Feb 13, 2025

Athira Pharma (ATHA) Expected to Announce Earnings on Thursday - Defense World

Feb 13, 2025
pulisher
Jan 30, 2025

Alterity stock jumps on data for lead drug (ATHA:NASDAQ) - Seeking Alpha

Jan 30, 2025
pulisher
Jan 28, 2025

Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth? - Yahoo Finance

Jan 28, 2025
pulisher
Jan 21, 2025

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - MSN

Jan 21, 2025
pulisher
Jan 17, 2025

Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m - Simply Wall St

Jan 17, 2025
pulisher
Jan 14, 2025

Keeping Fraud Out of Research: Government Grant Whistleblower Awarded Over $200,000 - The National Law Review

Jan 14, 2025
pulisher
Jan 14, 2025

Will Athira Pharma See A Boost From LIFT-AD Trial Results In Alzheimer's Research? - RTTNews

Jan 14, 2025
pulisher
Jan 10, 2025

Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement - Being Patient

Jan 10, 2025
pulisher
Jan 08, 2025

Athira to pay $4M to resolve research misconduct allegations - BioWorld Online

Jan 08, 2025
pulisher
Jan 08, 2025

ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 - MSN

Jan 08, 2025
pulisher
Jan 08, 2025

Bothell's Athira Pharma to pay $4M to settle falsified research claims - The Business Journals

Jan 08, 2025
pulisher
Jan 07, 2025

Biotech company agrees to pay $4 million to settle data falsification allegations - Retraction Watch

Jan 07, 2025
pulisher
Jan 06, 2025

Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud - Law360

Jan 06, 2025
pulisher
Jan 06, 2025

Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act Allegations Related to Scientific Research - U.S. Politics Today

Jan 06, 2025
pulisher
Jan 06, 2025

Athira Pharma to Pay $4 Million Over Alleged Research Misconduct - Marketscreener.com

Jan 06, 2025
pulisher
Jan 06, 2025

Bothell pharma company to pay $4 million over falsified research claims - MSN

Jan 06, 2025
pulisher
Jan 06, 2025

Athira Pharma Settles Claims of NIH Research Grant Misconduct - Bloomberg Law

Jan 06, 2025
pulisher
Jan 04, 2025

Athira Pharma CEO sells shares worth $14,107 By Investing.com - Investing.com South Africa

Jan 04, 2025
pulisher
Jan 03, 2025

Athira Pharma CEO sells shares worth $14,107 - Investing.com

Jan 03, 2025
pulisher
Jan 03, 2025

Athira Pharma VP of Finance Sells Shares for $1,618 - Investing.com India

Jan 03, 2025
pulisher
Jan 03, 2025

Athira Pharma VP of Finance Sells Shares for $1,618 By Investing.com - Investing.com Canada

Jan 03, 2025
pulisher
Dec 25, 2024

JMP Securities Downgrades Athira Pharma (ATHA) - MSN

Dec 25, 2024
pulisher
Dec 18, 2024

Athira Pharma Insider Ups Holding By 111% During Year - Yahoo Finance

Dec 18, 2024
pulisher
Dec 13, 2024

Athira Pharma's SWOT analysis: stock faces challenges after trial setback - Investing.com India

Dec 13, 2024

Athira Pharma Inc (ATHA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Athira Pharma Inc 주식 (ATHA) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
San Martin Javier
CHIEF MEDICAL OFFICER
Jan 02 '25
Sale
0.56
10,826
6,083
35,841
Litton Mark James
President and CEO
Dec 31 '24
Option Exercise
0.00
108,333
0
267,698
Litton Mark James
President and CEO
Jan 02 '25
Sale
0.56
25,107
14,108
242,591
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Dec 31 '24
Option Exercise
0.00
36,667
0
139,271
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Jan 02 '25
Sale
0.56
8,510
4,782
130,761
Renninger Robert
VP of Finance
Dec 31 '24
Option Exercise
0.00
12,359
0
92,605
Renninger Robert
VP of Finance
Jan 02 '25
Sale
0.56
2,881
1,619
89,724
Worthington Mark
General Counsel and CCO
Dec 31 '24
Option Exercise
0.00
36,667
0
92,245
Worthington Mark
General Counsel and CCO
Jan 02 '25
Sale
0.56
8,510
4,782
83,735
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
자본화:     |  볼륨(24시간):